Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy and primary ...
The phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo in adult kidney transplant recipients diagnosed with late antibody-mediated ...
The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo in adult kidney transplant recipients diagnosed with late antibody-mediated ...
Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...
Biogen BIIB announced that dosing has begun in a phase III study evaluating its key pipeline candidate, felzartamab, in adult kidney transplant recipients diagnosed with late antibody-mediated ...
Zacks Investment Research on MSN15d
BIIB Starts Felzartamab Phase III Study in AMR in Kidney TransplantBiogen BIIB announced that dosing has begun in a phase III study evaluating its key pipeline candidate, felzartamab, in adult kidney transplant recipients diagnosed with late antibody-mediated ...
Credit: sasirin pamai / Shutterstock. US-based biotechnology company Biogen has begun dosing in the Phase III TRANSCEND trial to assess felzartamab in adult kidney transplant recipients with late ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback